SCHEMBL6323367

SCHEMBL6323367

COc1cc(CNCCC(=O)NOC(C)(C)C)ccc1OCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.61
ALDH1A1 P00352 3/20 0.56
CYP2D6 P10635 2/20 0.56
CYP2C19 P33261 2/20 0.56
NPC1 O15118 1/20 0.53
PKM P14618 1/20 0.53
RAB9A P51151 1/20 0.53
LMNA P02545 3/20 0.53
HTT P42858 3/20 0.53
KDM4E B2RXH2 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
MTNR1A P48039 2/20 0.53
MTNR1B P49286 2/20 0.53
NPY1R P25929 1/20 0.53
NPY2R P49146 1/20 0.53
KMT2A Q03164 1/20 0.53
HTR1A P08908 1/20 0.52
HTR7 P34969 1/20 0.52
HTR6 P50406 1/20 0.52
CYP3A4 P08684 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14078228 0.80 BCHE (0.62) BCHEALDH1A1CYP2D6CYP2C19NPC1
SCHEMBL3465010 0.80 BCHE (0.62) BCHEALDH1A1CYP2D6CYP2C19NPC1
SCHEMBL6136381 0.80 BCHE (0.64) BCHEALDH1A1CYP2D6CYP2C19NPC1
Hydrochloric Acid SCHEMBL4949263 0.80 BCHE (0.77) BCHEALDH1A1NPC1PKMRAB9A
SCHEMBL5113589 0.79 BCHE (0.69) BCHEALDH1A1CYP2D6CYP2C19NPC1
SCHEMBL6326223 0.79 TRPM8 (0.56) ALDH1A1CYP2D6NPC1PKMRAB9A
SCHEMBL5315461 0.78 BCHE (0.67) BCHEALDH1A1NPC1PKMRAB9A
SCHEMBL3051565 0.77 LMNA (0.74) BCHEALDH1A1NPC1PKMRAB9A
SCHEMBL9416614 0.76 LMNA (0.73) BCHEALDH1A1NPC1PKMRAB9A
SCHEMBL19532621 0.76 BCHE (1.00) BCHEALDH1A1CYP2D6CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050228017-A1 Novel anticancer compounds MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE 2005-10-13 US disclosed
EP-1442018-A1 NOVEL ANTICANCER COMPOUNDS Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) 2004-08-04 EP disclosed
WO-2003037865-A1 NOVEL ANTICANCER COMPOUNDS Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228017-A1 Novel anticancer compounds TP53, ABCG2, MCL1 BCHE 3800/4885ALDH1A1 211/4885CYP2D6 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.